Kairos Pharma, Ltd. KAPA
1.72
(0.05)
(2.82%)
as of 25 Sep
- Market cap
- $6.1M
- P/E
- 0.0×
Follow KAPA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
16.56 | 27.07 | 10.31 | 11.98 |
Net Debt/EBITDA |
9.02 | 4.59 | 3.01 | 2.57 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.60 | 0.79 | 0.63 | 0.73 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.29) | (0.41) | (0.35) | (0.33) | |
Cash per Share |
2.30 | 2.03 | 1.43 | 0.99 | |
Shareholders Equity per Share |
2.65 | 2.41 | 1.77 | 1.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.65 | 2.41 | 1.77 | 1.37 | |
Free Cash Flow |
(0.84) | (1.08) | (1.04) | (1.01) | |
Working Capital |
6.25 | 5.19 | 4.01 | 2.91 | |
Net Current Asset Value |
6.25 | 5.19 | 4.01 | 2.91 | |
| Other line items | |||||
Quick Ratio |
16.50 | 26.81 | 9.98 | 11.46 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.29) | (0.41) | (0.35) | (0.33) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.97 | 0.60 | 0.62 | 0.47 | |
Average Assets |
6.54 | 6.15 | 6.84 | 5.56 | |
Average Common Equity |
5.50 | 5.56 | 6.22 | 5.09 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates